The Plasma Cholinesterase Activity as a Marker of Effectiveness of Rivastigmine by Koji Hori in TBSND - Juniper publisheers
In Japan, three medicines are available as a cholinesterase inhibitor for mild to moderate stage in Alzheimer's type dementia, i.e. donepezil, galantamine and rivastigmine. In Japan, donepezil was allowed in 1999 and other two medicines were allowed in 2011. Therefore, main separation of these three medicines is those between donepezil and (rivastigmine or galantamine). In this article we note the separation between donepezil and rivastigmine.
There is no convention and rule for using these three medicines for different purposes. Of course no separation between donepezil and rivastigmine. In fact, physicians are not conscious about the differentiation of these three medicines. It is only emphasized that rivastigmine is available as patch type and two medicines are available as oral administration type. Therefore, in the situation of prescription of rivastigmine, it is emphasized that we should prescribe rivastigmine when the patient refuse to take medicine.
No comments:
Post a Comment